IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

被引：0

作者：

Divya Thiagarajan

Nina Oparina

Susanna Lundström

Roman Zubarev

Jitong Sun

Marta Alarcon-Riquelme

Johan Frostegård

机构：

[1] Karolinska Institutet,Unit of Immunology and Chronic Disease, Institute of Environmental Medicine

[2] Karolinska Institutet,Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics

[3] GENYO,Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique

[4] Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government,Servicio Cantabro de Salud

[5] Parque tecnolуgico de la salud,Hospital Clinic I Provicia

[6] Referral Center for Systemic Autoimmune Diseases,Servicio Andaluz de Salud

[7] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Servicio Andaluz de Salud

[8] Centre Hospitalier Universitaire de Brest,Servicio Andaluz de Salud

[9] Hospital de la Cavale Blanche,Servicio Andaluz de Salud

[10] Université catholique de Louvain,undefined

[11] Centro Hospitalar do Porto,undefined

[12] Hospital Universitario Marqués de Valdecilla,undefined

[13] Institut d’Investigacions Biomèdiques August Pi i Sunyer,undefined

[14] Katholieke Universiteit Leuven,undefined

[15] Klinikum der Universitaet zu Koeln,undefined

[16] Medizinische Hochschule Hannover,undefined

[17] Medical University Vienna,undefined

[18] Hospital Universitario Reina Sofía Córdoba,undefined

[19] Complejo hospitalario Universitario de Granada (Hospital Universitario San Cecilio),undefined

[20] Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves),undefined

[21] Hospital Regional Universitario de Málaga,undefined

[22] Università degli studi di Milano,undefined

[23] Hospitaux Universitaires de Genève,undefined

[24] University of Szeged,undefined

[25] Charite,undefined

[26] Andalusian Public Health System Biobank,undefined

来源：

Scientific Reports | / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.

引用

共 76 条

[21]

Binder CJ(2016)IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms Clinical immunology 166–167 75-333

[22]

Frostegard J(2018)Moving towards a molecular taxonomy of autoimmune rheumatic diseases Nat Rev Rheumatol 14 36-200

[23]

Su J(2018)IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors Atherosclerosis 268 e000783-531

[24]

Anania C(2017)SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics Sci Rep 7 326-4559

[25]

Su J(2018)Mixed connective tissue disease: state of the art on clinical practice guidelines RMD Open 4 192-6043

[26]

Vas J(2017)Mixed connective tissue disease-enigma variations? Rheumatology (Oxford) 56 526-630

[27]

Gronwall C(2005)Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations Arthritis Rheum 52 4551-8400

[28]

Marshak-Rothstein A(2012)The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study Atherosclerosis 224 6031-304

[29]

Silverman GJ(2014)Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult J Immunol 192 619-1339

[30]

Gleissner CA(2009)IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells J Immunol 182 8392-2218

← 1 2 3 4 5 6 7 8 →